| 001 | 155422 | ||
| 005 | 20210129214105.0 | ||
| 024 | 7 | _ | |a 10.1007/s11060-014-1594-z |2 doi |
| 024 | 7 | _ | |a WOS:000345286700028 |2 WOS |
| 037 | _ | _ | |a FZJ-2014-04588 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Langen, K. J. |0 P:(DE-Juel1)131777 |b 0 |e Corresponding Author |u fzj |
| 245 | _ | _ | |a Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460] |
| 260 | _ | _ | |a Dordrecht [u.a.] |c 2014 |b Springer Science + Business Media B.V |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1416471104_16336 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 520 | _ | _ | |a o the Editor,We have read with interest the review by Ryken et al. about the role of imaging in the management of progressive glioblastoma [1]. In general, we agree with this review but we cannot support the opinion that the routine use of Positron-Emission-Tomography (PET) to identify progression of glioblastoma is not recommendable.The authors have considered PET using the amino acid tracer 11C-methyl-l-methionine (MET), but the use of MET is limited to PET centers with an on-site cyclotron due the short half-life of 11C (20.4 min). In recent years, the clinical application of 18F-labeled amino acids such as O-(2-18F-fluoroethyl)-l-tyrosine (FET) or 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine (FDOPA) has spread considerably due to the logistical advantages of the 18F label (half-life, 109.8 min) [2]. FET can be produced with high yields similar to the widely used FDG and distributed in a satellite concept [3]. In Europe, MET PET has been replaced in many centers by the more convenie ... |
| 536 | _ | _ | |a 333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333) |0 G:(DE-HGF)POF2-333 |c POF2-333 |f POF II |x 0 |
| 536 | _ | _ | |a 89572 - (Dys-)function and Plasticity (POF2-89572) |0 G:(DE-HGF)POF2-89572 |c POF2-89572 |x 1 |f POF II T |
| 700 | 1 | _ | |a Tonn, J. C. |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Weller, M. |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Galldiks, N. |0 P:(DE-Juel1)143792 |b 3 |u fzj |
| 773 | _ | _ | |a 10.1007/s11060-014-1594-z |0 PERI:(DE-600)2007293-4 |n 3 |p 665-666 |t Journal of neuro-oncology |v 120 |y 2014 |x 0167-594x |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/155422/files/FZJ-2014-04588.pdf |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:155422 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)131777 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)143792 |
| 913 | 2 | _ | |a DE-HGF |b POF III |l Key Technologies |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-572 |2 G:(DE-HGF)POF3-500 |v Decoding the Human Brain |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Funktion und Dysfunktion des Nervensystems |1 G:(DE-HGF)POF2-330 |0 G:(DE-HGF)POF2-333 |2 G:(DE-HGF)POF2-300 |v Pathophysiological Mechanisms of Neurological and Psychiatric Diseases |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF2 |
| 913 | 1 | _ | |a DE-HGF |0 G:(DE-HGF)POF2-89572 |v (Dys-)function and Plasticity |x 1 |4 G:(DE-HGF)POF |1 G:(DE-HGF)POF3-890 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-800 |b Programmungebundene Forschung |l ohne Programm |
| 914 | 1 | _ | |y 2014 |
| 915 | _ | _ | |a JCR/ISI refereed |0 StatID:(DE-HGF)0010 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| 981 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::